^
Association details:
| Biomarker: | MYC amplification |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Talzenna (talazoparib) (PARP inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
A retrospective analysis of association of MYC and RAD21 amplification with final overall survival (OS) data in the phase 3 EMBRACA study with talazoparib
Published date:
11/17/2020
Excerpt:
Baseline tumor tissue from 308 pts (71%; intent-to-treat) was tested by FoundationOne®...In TNBC pts receiving TALA, OS was shorter with MYC amplification than without...
Trial ID:
Test:
